Germany's BioNTech on Monday lifted its 2025 revenue guidance after receiving initial payments from its new partner Bristol Myers Squibb in a cancer immunotherapy alliance that seeks to challenge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback